https://www.selleckchem.com/pr....oducts/8-bromo-camp.
Colistin remains a last-line antibiotic for the treatment of multi-drug-resistant Acinetobacter species. However, mortality rates are high in patients with Acinetobacter infection receiving colistin treatment. This multi-center study evaluated whether colistin susceptibility, additional antimicrobial agents, or other prognostic factors influenced the clinical outcomes of patients receiving colistin treatment for Acinetobacter bacteremia. This retrospective study enrolled 122 adults receiving colistin treatment for monomicrobial Aci
Like
Comment
Share
